The MCP-1 Gene (SCYA2) and mood disorders: Preliminary results of a case-control association study

NeuroImmunoModulation

Volumn 17, Issue 2, 2010, Pages 126-131

  Altamura, A Carlo ^a   Mundo, Emanuela ^a   Cattaneo, Elisabetta ^a   Pozzoli, Sara ^a   Dell'Osso, Bernardo ^a   Gennarelli, Massimo ^e   Vergani, Carlo ^b   Trabattoni, Daria ^c   Arosio, Beatrice ^b   Clerici, Mario ^c,d  

^a Department of Psychiatry ^*  (United States)

^b Endocrine Surgery   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d Don Carlo Gnocchi Foundation Onlus IRCSS   (United States)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

MCP 1; Mood disorders

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE; GENOTYPE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MCP 1 GENE; MONOCYTE; MOOD DISORDER; PRIORITY JOURNAL; SUICIDE ATTEMPT;

ADULT; AGED; BIPOLAR DISORDER; BRAIN; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DEPRESSIVE DISORDER, MAJOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; POLYMORPHISM, GENETIC; SUICIDE, ATTEMPTED;

EID: 70449671190     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258696     Document Type: Article

References (40)

1. Altamura AC, Boin F, Maes M: HPA axis and cytokine dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 1991; 10: 1-4.
2. Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ: The immune system and schizophrenia. An integrative view. Ann NY Acad Sci 2000; 917: 456-467.
3. Na KS, Kim YK: Monocytic, Th1 and Th2 cytokine alteration in the pathophysiology of schizophrenia. Neuropsychobiology 2007; 56: 55-63.
4. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systemic quantitative review. Biol Psychiatry 2008; 63: 801-808.
5. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
6. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB: Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1044-1053.
7. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK: A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 230-233.
8. O'Brien SM, Scully P, Scott LV, Dinan TG: Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263-267.
9. Kim YK, Jung HG, Myint AM, Kim H, Park SH: Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-95.
10. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Goka E: IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473-476.
11. Tsao CW, Lin YS, Chen, CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 899-905.
12. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M: Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199-206.
13. Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5: 401-412.
14. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331.
15. Craddock N, Jones I: Genetics of bipolar disorder. J Med Genet 1999; 36: 585-594.
16. Mundo E, Zai G, Lee L, Parikh SV, Kennedy JL: The 5HT1Dbeta receptor gene in bipolar disorder: a family-based association study. Neuropsychopharmacology 2001; 25: 608-613. (Pubitemid 32830965)
17. Jun TY, Pae CU, Han H, Chae JH, Bahk WM, Kim KS, Kwon YS, Serretti A: Possible association between -G308A tumor necrosis factor- alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003; 13: 179-181. (Pubitemid 37082979)
18. Fertuzinhos SM, Oliveira JR, Nishimura AL, Pontual D, Carvalho DR, Sougey EB, Otto PA, Zatz M: Analysis of IL-1α, IL-1β, and IL- 1RA polymorphisms in dysthymia. J Mol Neurosci 2004; 22: 251-256.
19. Aiello RJ, Bourassa PK, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 1518-1525.
20. Daly C, Rollins BJ: Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 2003; 10: 247-257.
21. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, Julkunen I, Forster R, Burgstahler R, Lipp M, Lanzavecchia A: Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617-1625.
22. Gangur V, Birmingham NP, Thanesvorakul S: Chemokines in health and disease. Vet Immunol Immunopathol 2002; 86: 127-136.
23. Hanna J, Mussaffi H, Steuer G, Hanna S, Deeb M, Blau H, Arnon TI, Weizman N, Mandelboim O: Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood 2005; 106: 3465-3473.
24. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404: 407-411.
25. Luther SA, Cyster JG: Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-107.
26. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ: Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein-1 deficient mice. J Exp Med 1998; 187: 601-608.
27. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ: Human monocyte chemoattractant protein-1 (MCP-1). Fulllength cDNA cloning, expression in mitogen- stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989; 244: 487-493.
28. Rollins BJ, Morton CC, Ledbetter DH, Eddy RL Jr, Shows TB: Assignment of the human small inducible cytokine A2 gene, SCYA2 (encoding JE or MCP-1), to 17q11.2-12: evolutionary relatedness of cytokines clustered at the same locus. Genomics 1991; 10: 489-492.
29. Rovin BH, Lu L, Saxena R: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259: 344-348.
30. Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, Montresor C, Gennarelli M: MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 2005; 132: 1-4.
31. Pae CU, Yu HS, Kim TS, Lee CU, Lee SJ, Jun TY, Lee C, Serretti A, Paik IH: Monocyte chemoattractant protein-1 (MCP-1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004; 127: 279-281. (Pubitemid 39024505)
32. Pae CU, Kim TS, Jang WY, Kim JJ, Lee CU, Lee SJ: Monocyte chemoattractant protein-1 (MCP-1) -2518 polymorphism and bipolar I disorder. J Korean Neuropsychiatr Assoc 2004; 43: 524-528.
33. Roh MS, Lee KY, Joo EJ, Lee N, Kim YS: No association of the MCP-1 promoter A-2518G polymorphism with bipolar disorder in the Korean population. Neurosci Lett 2007; 427: 1-5.
34. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSMIV- TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, New York State Psychiatric Institute, Biometric Research, 2002.
35. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSMIV- TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York, New York State Psychiatric Institute, Biometric Research, 2002.
36. Maxwell ME: The Family Interview for Genetic Studies Manual. Washington, National Institute of Mental Health, Intramural Research Program, Clinical Neurogenetics Branch, 1992.
37. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
38. Maes M: Major depression and activation of the inflammatory response system; in Dantzer R, Wollman EE, Yirmiya R (eds): Cytokines, Stress and Depression. New York, Kluwer Academic/Plenum Publishers, 1999, pp 25-46.
39. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
40. Pae CU, Chung KI, Kim JJ, Yu HS, Lee CU, Lee SJ: Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. Psychiatr Genet 2004; 14: 65-67.